Brief Report: A Prospective Open-Label Phase IIa Trial of Tocilizumab in the Treatment of Polymyalgia Rheumatica Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Humanized
  • Immunologic Factors
  • Polymyalgia Rheumatica

abstract

  • Our findings suggest that TCZ may be an effective, safe, and well-tolerated treatment for newly diagnosed patients with PMR, with a robust steroid-sparing effect.

publication date

  • October 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/art.39740

PubMed ID

  • 27159185

Additional Document Info

start page

  • 2550

end page

  • 4

volume

  • 68

number

  • 10